Kezar Life Sciences
Yahoo Finance • last year
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 09, 2023--(BUSINESS WIRE)--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, t... Full story
Yahoo Finance • 2 years ago
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
PALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis to initiate in first half of 2023 KZR-261 dose escalation study currently enrolling sixth cohort; the dose expansion study expected to initiate in second half of 2... Full story
Yahoo Finance • 2 years ago
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritis Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer Cash, cash equivalents and ma... Full story
Yahoo Finance • 2 years ago
Healthcare Breakthroughs: KZR, NMLSF, AGRX, LMLLF Report Latest Advances in Novel Therapeutics for Inflammatory Diseases, Oncology, and Autism
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Kezar Life Sciences (NASDAQ: KZR), Nova Mentis Life... Full story
Yahoo Finance • 3 years ago
VOX PROVIDES DEVELOPMENT & EXPLORATION UPDATES
TORONTO, April 5, 2022 /CNW/ - Vox Royalty Corp. (TSXV: VOX) (OTCQX: VOXCF) ("Vox" or the "Company"), a high growth precious metals focused royalty company, is pleased to provide recent development and exploration updates from royalty oper... Full story
